D. Stock

发表

The Value of Backup Compounds to Drug Development Programs

P. Molinoff, D. Stock, 2002 .

Efficacy, safety, bone and metabolic effects of HIV nucleoside reverse transcriptase inhibitor BMS-986001 (AI467003): a phase 2b randomised, controlled, partly blinded trial.

Samit R. Joshi, G. McComsey, Samir K. Gupta, 2016, The lancet. HIV.

Safety and efficacy of the HIV-1 attachment inhibitor prodrug BMS-663068 in treatment-experienced individuals: 24 week results of AI438011, a phase 2b, randomised controlled trial.

Samit R. Joshi, J. Bogner, G. Hanna, 2015, The lancet. HIV.

A Phase 2b randomised, controlled, partially blinded trial of the HIV Nucleoside Reverse Transcriptase Inhibitor BMS-986001 (AI467003): Weeks 24 and 48 Efficacy, Safety, Bone and Metabolic Results

Samit R. Joshi, G. McComsey, Samir K. Gupta, 2016 .

BMS-927711 for the acute treatment of migraine: A double-blind, randomized, placebo controlled, dose-ranging trial

D. Dodick, P. Goadsby, G. Manos, 2014, Cephalalgia : an international journal of headache.

Evaluation of reverse transcriptase and protease inhibitors in two-drug combinations against human immunodeficiency virus replication

T. Chou, R. Colonno, T C Chou, 1996, Antimicrobial agents and chemotherapy.

BMS-232632, a Highly Potent Human Immunodeficiency Virus Protease Inhibitor That Can Be Used in Combination with Other Available Antiretroviral Agents

David A. Stock, R. Colonno, W. Blair, 2000, Antimicrobial Agents and Chemotherapy.

Safety and Efficacy of the HIV-1 Attachment Inhibitor Prodrug Fostemsavir in Antiretroviral-Experienced Subjects: Week 48 Analysis of AI438011, a Phase IIb, Randomized Controlled Trial

Samit R. Joshi, P. Cahn, R. Kaplan, 2017, Antiviral therapy.

In Vitro Antiviral Characteristics of HIV-1 Attachment Inhibitor BMS-626529, the Active Component of the Prodrug BMS-663068

N. Meanwell, M. Krystal, J. Kadow, 2012, Antimicrobial Agents and Chemotherapy.

Viral Drug Resistance Through 48 Weeks, in a Phase 2b, Randomized, Controlled Trial of the HIV-1 Attachment Inhibitor Prodrug, Fostemsavir

Samit R. Joshi, M. Krystal, G. Hanna, 2017, Journal of acquired immune deficiency syndromes.

HIV-1 attachment inhibitor prodrug BMS-663068 in antiretroviral-experienced subjects: week 24 sub-group analysis

J. Lalezari, M. Thompson, D. Stock, 2014, Journal of the International AIDS Society.

International Congress of Drug Therapy in HIV Infection 23-26 October 2016, Glasgow, UK

Raúl Tabarés Gutiérrez, Samit R. Joshi, H. Jessen, 2016, Journal of the International AIDS Society.

Safety and effi cacy of the HIV-1 attachment inhibitor prodrug BMS-663068 in treatment-experienced individuals : 24 week results of AI 438011 , a phase 2 b , randomised controlled trial

Samit R. Joshi, J. Bogner, G. Hanna, 2015 .

International Congress of Drug Therapy in HIV Infection 2‐6 November 2014, Glasgow, UK

Samit R. Joshi, Charlene A Flash, Thomas Lengauer, 2014 .

In Vitro Resistance Profile of the Human Immunodeficiency Virus Type 1 Protease Inhibitor BMS-232632

Timothy P. Spicer, Ronald E. Rose, T. Spicer, 2000, Antimicrobial Agents and Chemotherapy.

Safety, efficacy, and dose response of the maturation inhibitor GSK3532795 (formerly known as BMS-955176) plus tenofovir/emtricitabine once daily in treatment-naive HIV-1-infected adults: Week 24 primary analysis from a randomized Phase IIb trial

Samit R. Joshi, J. Bogner, J. Molina, 2018, PloS one.

Soluble Aβ and cognitive function in aged F-344 rats and Tg2576 mice

V. Gribkoff, J. Toyn, D. Barten, 2006, Behavioural Brain Research.

An Empirical Process for the Design of High-Throughput Screening Deck Filters

Andrew C. Good, David A. Stock, Bradley C. Pearce, 2006, J. Chem. Inf. Model..

4-Thiazolidinones: novel inhibitors of the bacterial enzyme MurB.

H. T. Ho, M. Deshpande, W. Harte, 2000, Bioorganic & medicinal chemistry letters.